Clinical Trial: A single‑arm, multicenter clinical study of Relatrafusp alfa injection, a recombinant PD‑L1/TGF‑βRII bifunctional fusion protein, combined with SOX as neoadjuvant therapy for gastric or gastroesophageal junction adenocarcinoma (China)

China, Sept. 23 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single‑arm, multicenter clinical study of Relatrafusp alfa injection, a recombinant PD‑L1/TGF‑βRII bifunctional fusion protein, combined with SOX as neoadjuvant therapy for gastric or gastroesophageal junction adenocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133177

Registration Time: 2026/09/22

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340487

Published by HT Digital Content Service...